Theranica

Neuromodulation-based Patch for Migraine Relief

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in November 2015 by Shimon Eckhouse, Alon Ironi, Ronen Jashek, and Slava Barabash, Theranica operates with 51–200 employees. The company has raised a total of $88.1 million across 5 funding rounds from 10 investors. In August 2022, Theranica secured a Series C funding round with New Rhein Healthcare Investors as a lead investor.

Business overview

Theranica is a digital therapeutics company focused on developing advanced, clinically proven, and affordable solutions for neurological pain conditions. Its core product, Nerivio, is a neuromodulation-based therapeutic patch controlled by a smartphone application, designed for migraine relief. The company leverages electrical neurostimulation and neuromuscular stimulation technologies to deliver effective treatments for severe and common medical problems, primarily serving patients in the Health Tech & Life Sciences sector.

Strategic signal

In September 2023, Theranica announced a new study indicating the meaningful impact of its Nerivio device from as early as two weeks. This demonstrates continued clinical validation and reinforces the efficacy of its neuromodulation technology, signaling strong potential for broader adoption and positive patient outcomes in the migraine treatment market.

Company Intelligence Q&A

What is Theranica's primary product?
Theranica's primary product is Nerivio, a neuromodulation-based therapeutic patch designed for migraine relief, controlled via a smartphone application.
When did Theranica receive FDA clearance for Nerivio Migra?
In May 2019, Theranica's Nerivio Migra device received FDA De Novo clearance for the acute treatment of migraines.
Which investors participated in Theranica's Series C funding round?
In August 2022, Theranica secured a Series C funding round with New Rhein Healthcare Investors as a lead investor, joined by LionBird.
Has Theranica expanded its market reach for Nerivio?
In September 2020, Nerivio received CE Mark for use in Europe, expanding its market accessibility beyond the US.
What significant milestone did Nerivio achieve in terms of treatments?
In March 2021, Nerivio, Theranica's drug-free wearable, surpassed 100,000 migraine treatments in the US.

External links